InnoTherapy Inc (246960) - Net Assets
Based on the latest financial reports, InnoTherapy Inc (246960) has net assets worth ₩24.57 Billion KRW (≈ $16.65 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩75.35 Billion ≈ $51.06 Million USD) and total liabilities (₩50.78 Billion ≈ $34.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 246960 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩24.57 Billion |
| % of Total Assets | 32.61% |
| Annual Growth Rate | N/A |
| 5-Year Change | 19.89% |
| 10-Year Change | N/A |
| Growth Volatility | 75.58 |
InnoTherapy Inc - Net Assets Trend (2015–2024)
This chart illustrates how InnoTherapy Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of InnoTherapy Inc.
Annual Net Assets for InnoTherapy Inc (2015–2024)
The table below shows the annual net assets of InnoTherapy Inc from 2015 to 2024. Also explore how fast is InnoTherapy Inc growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩15.52 Billion ≈ $10.52 Million |
-17.91% |
| 2023-12-31 | ₩18.90 Billion ≈ $12.81 Million |
+44.90% |
| 2022-12-31 | ₩13.05 Billion ≈ $8.84 Million |
+29.43% |
| 2021-12-31 | ₩10.08 Billion ≈ $6.83 Million |
-22.13% |
| 2020-12-31 | ₩12.94 Billion ≈ $8.77 Million |
-14.19% |
| 2019-12-31 | ₩15.08 Billion ≈ $10.22 Million |
+58.46% |
| 2018-12-31 | ₩9.52 Billion ≈ $6.45 Million |
+207.38% |
| 2017-12-31 | ₩3.10 Billion ≈ $2.10 Million |
-49.02% |
| 2016-12-31 | ₩6.07 Billion ≈ $4.12 Million |
+197.51% |
| 2015-12-31 | ₩-6.23 Billion ≈ $-4.22 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to InnoTherapy Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3216936969000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩3.62 Billion | 23.32% |
| Other Components | ₩51.51 Billion | 331.98% |
| Total Equity | ₩15.52 Billion | 100.00% |
InnoTherapy Inc Competitors by Market Cap
The table below lists competitors of InnoTherapy Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ChowChow Cloud International Holdings Limited
NYSE MKT:CHOW
|
$13.44 Million |
|
Medifron DBT Co. Ltd
KQ:065650
|
$13.45 Million |
|
Salutica Bhd
KLSE:0183
|
$13.45 Million |
|
Adriatic Metals
LSE:ADT1
|
$13.45 Million |
|
Tira Austenite Tbk
JK:TIRA
|
$13.44 Million |
|
Vakif Menkul Kiymet Yatirim Ortakligi AS
IS:VKFYO
|
$13.43 Million |
|
Smartiks Yazilim AS
IS:SMART
|
$13.43 Million |
|
Mg Internation
PA:ALMGI
|
$13.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in InnoTherapy Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 18,902,868,460 to 15,517,324,180, a change of -3,385,544,280 (-17.9%).
- Net loss of 3,730,136,090 reduced equity.
- Other factors increased equity by 344,591,810.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-3.73 Billion | -24.04% |
| Other Changes | ₩344.59 Million | +2.22% |
| Total Change | ₩- | -17.91% |
Book Value vs Market Value Analysis
This analysis compares InnoTherapy Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 1.71x to 4.38x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1363.72 | ₩2335.00 | x |
| 2017-12-31 | ₩695.20 | ₩2335.00 | x |
| 2018-12-31 | ₩2136.89 | ₩2335.00 | x |
| 2019-12-31 | ₩2990.03 | ₩2335.00 | x |
| 2020-12-31 | ₩2565.84 | ₩2335.00 | x |
| 2021-12-31 | ₩1998.11 | ₩2335.00 | x |
| 2022-12-31 | ₩2329.54 | ₩2335.00 | x |
| 2023-12-31 | ₩2612.04 | ₩2335.00 | x |
| 2024-12-31 | ₩532.63 | ₩2335.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently InnoTherapy Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -78.74%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.55x
- Recent ROE (-24.04%) is above the historical average (-33.34%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 0.00% | -35369.61% | 0.00x | 0.00x | ₩-4.12 Billion |
| 2016 | -12.81% | -773.63% | 0.01x | 1.16x | ₩-1.39 Billion |
| 2017 | -97.27% | -1485.79% | 0.05x | 1.36x | ₩-3.32 Billion |
| 2018 | -27.05% | -502.60% | 0.05x | 1.17x | ₩-3.53 Billion |
| 2019 | -26.45% | -575.82% | 0.04x | 1.14x | ₩-5.50 Billion |
| 2020 | -23.55% | -511.16% | 0.03x | 1.34x | ₩-4.34 Billion |
| 2021 | -49.90% | -991.39% | 0.02x | 3.16x | ₩-6.04 Billion |
| 2022 | -45.78% | -1614.99% | 0.01x | 2.36x | ₩-7.28 Billion |
| 2023 | -26.59% | -380.17% | 0.04x | 1.60x | ₩-6.92 Billion |
| 2024 | -24.04% | -78.74% | 0.20x | 1.55x | ₩-5.28 Billion |
Industry Comparison
This section compares InnoTherapy Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $357,550,164,923
- Average return on equity (ROE) among peers: 3.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| InnoTherapy Inc (246960) | ₩24.57 Billion | 0.00% | 2.07x | $13.44 Million |
| Shinhung (004080) | $113.89 Billion | 8.10% | 0.23x | $92.12 Million |
| HansBiomed Corporation (042520) | $44.45 Billion | -41.14% | 1.91x | $159.48 Million |
| JVM Co. Ltd (054950) | $158.12 Billion | 9.96% | 0.47x | $179.92 Million |
| U&I Corporation (056090) | $59.07 Billion | -3.52% | 0.12x | $83.27 Million |
| Huvitz Co. Ltd (065510) | $103.01 Billion | 16.58% | 0.72x | $49.17 Million |
| Vieworks Co. Ltd (100120) | $70.90 Billion | 14.78% | 0.19x | $155.03 Million |
| Corentec Co Ltd (104540) | $20.12 Billion | 2.40% | 0.93x | $35.22 Million |
| SD Biosensor Inc (137310) | $2.95 Trillion | 30.93% | 0.11x | $483.95 Million |
| Hironic Co. Ltd (149980) | $43.93 Billion | 6.45% | 0.04x | $48.87 Million |
| Humasis Co. Ltd (205470) | $15.24 Billion | -8.04% | 1.39x | $208.19 Million |
About InnoTherapy Inc
SCL Science Inc. produces medical hemostatic agents using biomimetic technology. Its products include BiMM (Bio-inspired Medical Materials) that reacts immediately with blood; Endoseal, which is used for specialized indication of gastrointestinal bleeding; InnoSeal, a hemostatic agent that is used in various surgical fields, such as cardiology, radiology, and neurosurgery; Jelly Seal, a hemostasi… Read more